Your shopping cart is currently empty

Microtubule destabilizing agent-3, negative control, is an analog of B32B3 and serves as the negative control for Microtubule destabilizing agent-3. This agent functions as a microtubule destabilizer by disrupting microtubule stability, which promotes mitotic arrest and exhibits an anti-myeloma phenotype, ultimately leading to cell death. It can also induce G2/M phase arrest and caspase-dependent apoptosis.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | Microtubule destabilizing agent-3, negative control, is an analog of B32B3 and serves as the negative control for Microtubule destabilizing agent-3. This agent functions as a microtubule destabilizer by disrupting microtubule stability, which promotes mitotic arrest and exhibits an anti-myeloma phenotype, ultimately leading to cell death. It can also induce G2/M phase arrest and caspase-dependent apoptosis. |
| In vitro | Microtubule destabilizing agent-3, negative control (VPR4), does not demonstrate thermal stabilization of DCAF1 in CETSA. |
| In vivo | The study utilized C57Bl/6 and B6.SJL-Ptprca Pepcb/BoyJ (Ptprca) mice. A dosage of 15 mg/kg was administered intraperitoneally (i.p.) over a regimen of 5 consecutive days followed by a 2-day break. Results demonstrated a reduction in lymphoma progression biomarkers, such as spleen weight and peripheral blood and nodal tumor burden. Ten days of continued treatment significantly increased overall survival, extending the median from 17 days in the vehicle group to 22 days in the VPR8 group. The compound was effective in both tp53 wild-type and tp53-null EμMyc lymphoma models. |
| Molecular Weight | 310.42 |
| Formula | C17H18N4S |
| Cas No. | 2734582-91-1 |
| Smiles | N(=CC=1C=CC=CC1)NC=2N=CN=C3SC4CCCCC4C32 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.